CDKN2A and breast cancer: Considering the actionability of specific alterations based on OncoKB, CDKN2A homozygous deletion (level 4 evidence), and both oncogenic mutations in PIK3CA were considered clinically actionable (level 3A evidence for breast cancer, Table 2).